Adenocarcinomas of the Pancreas Clinical Trial
Official title:
Open-label Pilot Phase I / II Study on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Macroscopically Complete Resection (R0/R1) of Adenocarcinomas of the Pancreas (PanHIPEC)
In patients with peritoneal metastases of colorectal cancer could be a radical removal of all tumor foci a significantly improved survival compared to a sole systemic chemotherapy are additionally achieved by a hyperthermic intraoperative chemotherapy (HIPEC).
Despite medical progress in recent years in pancreatic reach the 5-year survival rates even
after radical surgical resection only 20%, which is due to high rates of local recurrence and
distant metastases in the postoperative course. Due to the anatomical position of the
pancreas resections are having a "wide margin" technically almost impossible, so that the
tumor on postoperative preparation is often marginal forming. A further possible explanation
for the high number of local recurrences, intraoperative tumor cell displacement in question.
In patients with peritoneal metastases of colorectal cancer could be a radical removal of all
tumor foci a significantly improved survival compared to a sole systemic chemotherapy are
additionally achieved by a hyperthermic intraoperative chemotherapy (HIPEC). Purpose of HIPEC
it is to kill any remaining microscopic residual tumor or residual tumor cells free. The aim
of the present phase I / II study is therefore to examine the importance of HIPEC in addition
to radical resection of ductal pancreatic cancer in terms of mortality and morbidity.
;